Posted: February 21, 2024 at 2:34 am
– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference –
Read more from the original source:
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
Posted: February 21, 2024 at 2:34 am
BOSTON and ROLLE, Switzerland, Feb. 20, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full-year 2023 before U.S. markets open on Tuesday, March 5, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.
Original post:
SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full-Year 2023 on March 5, 2024
Posted: February 21, 2024 at 2:34 am
CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2023 financial results will be released on Tuesday, February 27, 2024 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Posted: February 21, 2024 at 2:34 am
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in a corporate panel discussion on novel oncology targets at the Cowen 44th Annual Health Care Conference on Tuesday, March 5th, at 9:10 am ET.
Go here to read the rest:
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
Posted: February 21, 2024 at 2:34 am
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
Follow this link:
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
Posted: February 21, 2024 at 2:34 am
Innovations and know-how in exosome production suited for many clinical applications Innovations and know-how in exosome production suited for many clinical applications
Go here to read the rest:
NurExone’s Intellectual Property Portfolio Expands
Posted: February 21, 2024 at 2:34 am
BRISBANE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on February 16, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
Read the original post:
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Posted: February 21, 2024 at 2:34 am
- Sean Cassidy leaving Arvinas as of February 29, 2024 -
Read more:
Arvinas Announces Chief Financial Officer Transition
Posted: February 21, 2024 at 2:34 am
REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2023 on Monday, February 26, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and full year, and provide an update on corporate progress.
Follow this link:
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
Posted: February 21, 2024 at 2:34 am
Montrouge, France, February 20 2024
Read more:
DBV Technologies to Participate in Upcoming AAAAI 2024 Congress
